New Findings from Fujian Medical University Update Understanding of Lung Cancer (Perioperative Serplulimab-based Chemoimmunotherapy In Stage Iv Large Cell Neuroendocrine Carcinoma of the Lung: a Case Report).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      FUJIAN Sheng (China)
    • Abstract:
      A recent case report from Fujian Medical University in the People's Republic of China highlighted the successful treatment of a 45-year-old male with stage IV large cell neuroendocrine carcinoma of the lung using perioperative immunochemotherapy. Despite the typical non-recommendation of surgery for stage IV cases, the patient underwent neoadjuvant therapy followed by adjuvant and maintenance therapy, resulting in a clinical cure with no visible tumor or distant metastasis. The research concluded that immunochemotherapy showed efficacy in treating advanced LCNEC, with the patient experiencing event-free survival exceeding 11 months and overall survival exceeding 14 months. [Extracted from the article]
    • Abstract:
      Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)